POLYMER BULLETIN, cilt.80, sa.7, ss.7687-7714, 2023 (SCI-Expanded)
Pregabalin is widely
used in neurologic diseases such as epilepsy treatments and has a low half-life
in the body when taken in tablet form by mixing physically with some matrix. In
order to prolong therapeutic effect of pregabalin in system by means of
protecting the stability and activity of pregabalin, poly(methyl vinyl
ether-alt-maleic anhydride) copolymer is functionalized with pregabalin. For
this purpose, it is synthesized 6 copolymer-drug delivery systems which
pregabalin drug active material bonded to poly(methyl vinyl ether-alt-maleic
anhydride) copolymer in 3 different ratios in uncatalyzed media and in
triethylamine catalyst media. The approximate molecular weight of
copolymer-drug delivery systems and percent drug binding to copolymer are
calculated together with the structural characterization of the synthesized
copolymer-drug delivery systems by FT-IR/ATR and 1 H NMR
spectroscopy and morphological characterization via SEM, XRD and BET analysis.
To determine the optimum conditions in which these copolymer-drug delivery
systems are stable, Zetasizer measurements such as particle size and zeta
potential are made in different pH and artificial body fluids as a function of
time at 37 ℃. The optimum conditions at which these copolymer-drug delivery
systems maintain their activity is determined by UV/VIS spectrum measurements
in different pH and artificial body fluid environments depending on time.